Oncology

With FDA clearance for clinical trials, CanWell Pharma’s novel CAN016 ADC brings a two-pronged attack against drug-resistant HER2-positive cancers.

Expanded Medicare payment for RefleXion's SCINTIX therapy removes major financial hurdles, opening doors for advanced cancer care in community centers.

Delcath Systems is set to showcase its innovative HEPZATO KIT at SIR 2026, signaling growing adoption and a pivotal moment for its targeted cancer therapy.

Biotech veteran Dr. Vince O'Neill joins Mosaic Therapeutics to spearhead its synergistic precision oncology pipeline, aiming to transform cancer treatment.

A stark new benchmark study reveals poor survival in late-stage GvHD, just as MaaT Pharma’s microbiome therapy shows dramatically better outcomes.

Abbisko's irpagratinib gets EMA Orphan Drug status, fast-tracking a precision therapy for a hard-to-treat liver cancer subgroup with unmet needs.

The Our Health Our Wellness campaign aims to close critical health disparity gaps with resources, events, and education for underserved communities.

Facing a severe cash crunch and delisting threats, the biotech firm is halting development and seeking buyers for its innovative cancer drug pipeline.

A novel drug aims to break down resistance in hard-to-treat lung and bile duct cancers, with key data set for a major oncology conference.

The Polish biotech will showcase its STRIDE® platform at AACR 2026, promising more precise ways to measure cancer's response to therapy.

A new, imageable liver cancer therapy is one step closer to patients, thanks to a strategic partnership securing a vital US-based medical isotope supply.

Final trial data shows pralsetinib offers years of survival for RET+ lung cancer, but realizing its full potential hinges on overcoming diagnostic hurdles.

A new, highly selective oral drug for the most common form of dwarfism has been cleared for U.S. trials, offering hope for a more convenient treatment.

Formerly Asha Therapeutics, the biotech rebrands with top talent and an AI platform that designs novel medicines from scratch for humanity's toughest diseases.

An amended deal with Tasly positions AP Biosciences to license its innovative bispecific cancer therapy to global pharma giants, targeting a lucrative market.

As Precigen leaders prepare for a key investor chat, all eyes are on the explosive launch of PAPZIMEOS and the company's ambitious path to profitability.

Global CRO ChemPartner launches a new research site in Kent's Discovery Park, a major strategic push to accelerate drug development for European clients.

With a fortified balance sheet and promising clinical data, Monopar Therapeutics is advancing its lead drug, ALXN1840, toward a pivotal NDA filing.

Dr. Lisa G. Roth, a top oncologist and survivor, takes the helm at Hassenfeld, promising a new era of 'whole person' care for young cancer patients.

With a $150M war chest, OnKure pivots to a new class of PI3Kα inhibitors, aiming to revolutionize treatment for breast cancer and rare diseases.